4-吗啉基(4-苯基-4-哌啶基)甲酮 | 83929-37-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 4-吗啉基(4-苯基-4-哌啶基)甲酮
• 英文名称: 4-(4-Phenylpiperidin-4-ylcarbonyl)morpholine hydrochloride
• 英文别名: morpholin-4-yl-(4-phenylpiperidin-4-yl)methanone;hydrochloride
• CAS: 83929-37-7
• 化学式: C₁₆H₂₂N₂O₂*ClH
• 分子量: 310.824
• InChiKey: BHPBCTQIGBZUCM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.59
• 重原子数：
  21
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  41.6
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-吗啉基(4-苯基-4-哌啶基)甲酮 、 Methanesulfonic acid 2-[(S)-3-(3,4-dichloro-phenyl)-1-(3,4,5-trichloro-benzoyl)-pyrrolidin-3-yl]-ethyl ester 在 potassium carbonate 作用下， 以 四氢呋喃 、 水 为溶剂， 生成
  参考文献：
  名称：

  Synthesis and structure-activity relationships for a series of substituted pyrrolidine NK1/NK2 receptor antagonists

  摘要：

  We recently described the synthesis and characterization of MDL 105,212, a non peptide tachykinin antagonist with high affinity for NK1 and NK2 receptors.(1) Here we report the synthesis and structure-activity relationships for a series of analogs of MDL 105,212 with regards to: NK1 and NK2 receptor binding affinity, physical-chemical characterization; in vitro absorption potential; in vitro metabolic stability; and efficacy in a capsaicin-challenge conscious guinea pig model after oral administration. (C) 1997 Elsevier Science Ltd.

  DOI：

  10.1016/s0960-894x(97)10013-0
• 作为产物：
  描述：

  保护的4-苯基哌啶-4-羧酸 在 盐酸 、 1-羟基苯并三唑 、 1-(3-二甲基氨基丙基)-3-乙基碳二亚胺 、 N,N-二异丙基乙胺 作用下， 以 1,4-二氧六环 、 二氯甲烷 为溶剂， 生成 4-吗啉基(4-苯基-4-哌啶基)甲酮
  参考文献：
  名称：

  Synthesis and structure-activity relationships for a series of substituted pyrrolidine NK1/NK2 receptor antagonists

  摘要：

  We recently described the synthesis and characterization of MDL 105,212, a non peptide tachykinin antagonist with high affinity for NK1 and NK2 receptors.(1) Here we report the synthesis and structure-activity relationships for a series of analogs of MDL 105,212 with regards to: NK1 and NK2 receptor binding affinity, physical-chemical characterization; in vitro absorption potential; in vitro metabolic stability; and efficacy in a capsaicin-challenge conscious guinea pig model after oral administration. (C) 1997 Elsevier Science Ltd.

  DOI：

  10.1016/s0960-894x(97)10013-0

文献信息

• DIPEPTIDES WHICH PROMOTE RELEASE OF GROWTH HORMONE
  申请人：PFIZER INC.

  公开号：EP0828754A1

  公开（公告）日：1998-03-18
• US5936089A
  申请人：——

  公开号：US5936089A

  公开（公告）日：1999-08-10
• [EN] DIPEPTIDES WHICH PROMOTE RELEASE OF GROWTH HORMONE<br/>[FR] DIPEPTIDES FAVORISANT LA SECRETION DE L'HORMONE DE CROISSANCE
  申请人：PFIZER INC.

  公开号：WO1996038471A1

  公开（公告）日：1996-12-05

  (EN) Compounds of formula (I) are growth hormone releasing peptide mimetics which are useful for the treatment and prevention of osteoporosis.(FR) L'invention se rapporte aux composés de la formule (I). Il s'agit de mimétiques des peptides favorisant la secrétion de l'hormone de croissance, qui sont utiles pour le traitement et la prévention de l'ostéoporose.
• [EN] DIPEPTIDES WHICH PROMOTE RELEASE OF GROWTH HORMONE<br/>[FR] DIPEPTIDES STIMULANT LA LIBERATION DE L'HORMONE DE CROISSANCE
  申请人：PFIZER, INC.

  公开号：WO1996035713A1

  公开（公告）日：1996-11-14

  (EN) Compounds of formula (I) are growth hormone releasing peptide mimetics which are useful for the treatment and prevention of osteoporosis.(FR) Les composés de formule (I) sont des substances mimétiques peptidiques libérant l'hormone de croissance, utiles pour traiter et prévenir l'ostéoporose.
• Synthesis and structure-activity relationships for a series of substituted pyrrolidine NK1/NK2 receptor antagonists
  作者：Timothy P. Burkholder、Elizabeth M. Kudlacz、George D. Maynard、Xiao-Gao Liu、Tieu-Binh Le、Mark E. Webster、Stephen W. Horgan、David L. Wenstrup、David W. Freund、Fred Boyer、Larry Bratton、Raymond S. Gross、Robert W. Knippenberg、Deborah E. Logan、Bryan K. Jones、Teng-Man Chen、Julie L. Geary、Melinda A. Correll、J. Chuck Poole、Arun K. Mandagere、Thomas N. Thompson、Kin-Kai Hwang

  DOI：10.1016/s0960-894x(97)10013-0

  日期：1997.10

  We recently described the synthesis and characterization of MDL 105,212, a non peptide tachykinin antagonist with high affinity for NK1 and NK2 receptors.(1) Here we report the synthesis and structure-activity relationships for a series of analogs of MDL 105,212 with regards to: NK1 and NK2 receptor binding affinity, physical-chemical characterization; in vitro absorption potential; in vitro metabolic stability; and efficacy in a capsaicin-challenge conscious guinea pig model after oral administration. (C) 1997 Elsevier Science Ltd.